EGFRvIII产品信息
英文名称:Epidermal growth factor receptor variant III
中文名称:表皮生长因子受体变体III
靶点别称:EGFRvIII,EGFRv3
物种:Human
属性:Protein / Beads
标记:Biotin-labeled / FITC Labeled / Unconjugated / PE Labeled / AF488 Labeled / APC Labeled
内毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
纯度(Purity)
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制剂(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
1. -20°C to -70°C for 12 months in lyophilized state;
2. -70°C for 3 months under sterile conditions after reconstitution.
EGFRvIII分子背景
The Human EGFRvIII-coupled Magnetic Beads is produced by coupling biotinylated EGFRvIII protein to streptavidin-conjugated magnetic beads. Because Streptavidin (SA) has an extraordinarily high affinity for biotin with a dissociation constant (Kd) on the order of 10-14 mol/L, the biotinylated protein can bind to the SA beads irreversibly. The pre-coupled beads are ready to use for capturing anti-EGFRvIII antibody from your sample with high specificity.
EGFRvIII用户评价
关键字: EGFRvIII;EGFRvIII蛋白;EGFRv3;EGFRv3蛋白;表皮生长因子受体;
百普赛斯集团ACROBiosystems Group(股票代码:301080)是成立于2010年的跨国生物科技公司,是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球,横跨亚洲、北美洲、欧洲,在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家,与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。